Retinoids and human breast cancer: in vivo effects of an antagonist for RAR-alpha.
The aim of the present study was to evaluate the in vivo effects of the RAR-alpha selective antagonist Ro 41-5253 on a xenograft animal model for breast cancer. Our observations indicate a lack of toxic side effects of the drug, even when used at high dosages. It is interesting to note that using Ro 41-5253 at dosages of 10, 30 and 100 mg/kg/die resulted in a slight, but significant inhibition of cell growth. The data obtained in this study represents the basis for a further evaluation of Ro 41-5253 anti-neoplastic activity on transgenic breast cancer animal models.
Toma
Salvatore
S
Department of Oncology, Biology and Genetics, University of Genoa, Genoa, Italy. toma@cba.unige.it
Emionite
Laura
L
Scaramuccia
Angelo
A
Ravera
Giambattista
G
Scarabelli
Linda
L
D000818:Animals; D001565:Benzoates / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D045744:Cell Line, Tumor; D002839:Chromans / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D051379:Mice; D018168:Receptors, Retinoic Acid / Q000037:antagonists & inhibitors*; D000072482:Retinoic Acid Receptor alpha; D012176:Retinoids / Q000633:toxicity*
D001565:Benzoates; D002839:Chromans; C000607071:RARA protein, human; C000607072:Rara protein, mouse; D018168:Receptors, Retinoic Acid; D000072482:Retinoic Acid Receptor alpha; D012176:Retinoids; C084904:Ro 41-5253